AGM/EGMJun 30, 2026, 04:36 PM
Biodexa AGM: Resolutions 8, 10, 11 Fail; Others Pass
AI Summary
Biodexa Pharmaceuticals PLC announced the results of its Annual General Meeting held on June 30, 2026. Ordinary resolutions 1 through 7 passed with significant majorities, ranging from 73% to 94%. However, ordinary resolution 8 and special resolution 10 failed to pass, leading to the contingent resolution 11 also failing. Biodexa is a clinical-stage biopharmaceutical company focused on gastrointestinal cancers and other diseases.
Key Highlights
- Annual General Meeting held on June 30, 2026.
- Ordinary resolutions 1 through 7 passed with majorities of 73% to 94%.
- Ordinary resolution 8 failed to pass.
- Special resolution 10 failed to pass.
- Resolution 11 failed as it was contingent on resolution 8.
- Biodexa is a clinical-stage biopharmaceutical company.
Price Impact
More from BDRX